3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
38
Carcinoma, Non-Small-Cell Lung
23
Stomach Neoplasms
19
Nasopharyngeal Carcinoma
19
Triple Negative Breast Neoplasms
18
Esophageal Squamous Cell Carcinoma
17
Esophageal Neoplasms
16
Breast Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Colorectal Neoplasms
11
Uterine Cervical Neoplasms
10
Pancreatic Neoplasms
8
Sarcoma
6
Recurrence
6
Neoplasm Metastasis
6
Melanoma
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Lung Neoplasms
5
Hodgkin Disease
5
Biliary Tract Neoplasms
5
Osteosarcoma
4
Neoplasms
4
Locally Advanced Gastric Cancer
4
Advanced Gastric Cancer
4
Rectal Neoplasms
3
Nasopharyngeal Neoplasms
3
Glioblastoma
3
Gestational Trophoblastic Disease
3
Urinary Bladder Neoplasms
2
Interventions
Cyclophosphamide
6
Granulocyte Colony-Stimulating Factor
5
Melphalan
4
Etoposide
4
Cisplatin
4
Carboplatin
4
sodium thiosulfate
3
fludarabine
3
Thiotepa
3
Mesna
3
Filgrastim
3
Busulfan
3
pembrolizumab
2
Vorinostat
2
Vincristine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Ifosfamide
2
Gemcitabine
2
Fluorouracil
2
Doxorubicin
2
talazoparib
1
sintilimab
1
sargramostim
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
lenvatinib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hepatoblastoma
×
camrelizumab
×
Clear all
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled